Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database

BACKGROUND: Mogamulizumab (Moga) is a C—C chemokine receptor-4 antibody approved in the United States for relapsed /refractory mycosis fungoides and Sézary syndrome. Few cases reported an increased risk of hepatitis B reactivation and cytomegalovirus (CMV) related infection post-Moga. However, liter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuai, Jayarangaiah, Apoorva, Malone, Mariuxi, Elrafei, Tarek, Steinberg, Lewis, Kumar, Abhishek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700953/
https://www.ncbi.nlm.nih.gov/pubmed/33294815
http://dx.doi.org/10.1016/j.eclinm.2020.100601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700953/
https://www.ncbi.nlm.nih.gov/pubmed/33294815
http://dx.doi.org/10.1016/j.eclinm.2020.100601

Ejemplares similares